EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility

Torben Brøchner Pedersen iD, Charlotte Aaberg Poulsen iD, Martin Lund iD, Maher Albitar iD, Louise Dorner Østergaard iD, Søren Feddersen iD, Lars Lund iD, Mads Hvid Poulsen iD

Scandinavian Journal of Urology · 04.03.2026 · 61 · 31-37

DOI: 10.2340/sju.v61.45464 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Scandinavian Journal of Urology, online erschienen am 04.03.2026. Verfasst von Torben Brøchner Pedersen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Odense University Hospital, Odense, Denmark. torben.b.pedersen@rsyd.dk. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Algorithms, Biomarkers, Tumor. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to compare test sensitivity for detecting aggressive prostate cancer and test specificity (measured by reduction in prostate biopsies) between algorithm-triage and standard systematic biopsy in elderly men with suspected prostate cancer.

Methods

This randomised controlled trial enrolled men ≥ 70 years old suspected of prostate cancer and randomised them 1:1 to algorithm-triage or standard systematic biopsies. The algorithm arm used a 10-gene mRNA panel from urine and plasma samples, integrated with clinical characteristics and PSA measurements to predict prostate cancer with International Society of Urological Pathology grade group ≥ 2. Patient-reported outcomes measures were collected using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores or subdomains throughout a 24-month follow-up. ClinicalTrials.gov: NCT04079699.

Results

A total of 202 men were included between October 2019 and September 2021. The study was terminated early due to algorithm underperformance. The algorithm-triage arm detected fewer indolent cancers (7.9% vs. 19%, absolute difference −10.9 percentage points, 95% confidence interval [CI]: −21.0 to −1.0 pp, P = 0.039) but also fewer clinically significant cancers (26% vs. 40%, absolute difference −13.9 percentage points, 95% CI: −27.6 to −0.1 pp, P = 0.051) compared to systematic biopsy. Patient-reported outcomes showed no significant between-group differences in FACT-P scores or subdomains throughout 24-month follow-up (differences 0.1–2.2 points, all P > 0.05), indicating comparable quality of life.

Conclusion

The biomarker-based algorithm-triage reduced biopsy numbers but also detected fewer ­clinically significant prostate cancers. Quality of life was comparable between approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAlgorithmsBiomarkers, TumorHumansMaleAgedBiopsyProstate-Specific AntigenAged, 80 and overSensitivity and Specificity

Substanzen

Biomarkers, TumorProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Odense University Hospital, Odense, Denmark. torben.b.pedersen@rsyd.dk.
  • Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
  • Department of Urology, Odense University Hospital, Odense, Denmark.
  • Genomic Testing Cooperative, Irvine, CA, USA.
  • Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark.
  • Department for Urology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark; Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark.

ORCID-Profile: Torben Brøchner Pedersen, Charlotte Aaberg Poulsen, Martin Lund, Maher Albitar, Louise Dorner Østergaard, Søren Feddersen, Lars Lund, Mads Hvid Poulsen

Zitieren

APA

Pedersen, T. B., Poulsen, C. A., Lund, M., Albitar, M., Østergaard, L. D., Feddersen, S., Lund, L., & Poulsen, M. H. (2026). Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility. Scandinavian Journal of Urology, 61, 31-37. https://doi.org/10.2340/sju.v61.45464

Vancouver

Pedersen TB, Poulsen CA, Lund M, Albitar M, Østergaard LD, Feddersen S, et al. Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility. Scandinavian Journal of Urology. 2026;61:31-37. doi:10.2340/sju.v61.45464

BibTeX
@article{Pedersen2026,
  author = {Pedersen, Torben Brøchner and Poulsen, Charlotte Aaberg and Lund, Martin and Albitar, Maher and Østergaard, Louise Dorner and Feddersen, Søren and Lund, Lars and Poulsen, Mads Hvid},
  title = {Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility},
  journal = {Scandinavian Journal of Urology},
  year = {2026},
  volume = {61},
  pages = {31--37},
  doi = {10.2340/sju.v61.45464}
}
Kostenlos starten →